Long acting GLP-1 receptor agonist (injectable)
Efpeglenatide 4 mg subcutaneous once weekly
EFPE_SC_4MG_QW
Related
- All doses pooled: Efpe sc
- Efpe sc 1mg qw
- Efpeglenatide 2 mg subcutaneous once weekly
- Efpe sc 8mg qm
- Efpe sc 12mg qm
- Efpeglenatide 16 mg injection monthly
- Efpeglenatide 8 mg injection every 4 weeks
- Efpeglenatide 12 mg injection every 4 weeks
- Efpeglenatide 16 mg injection every 4 weeks
- Efpeglenatide 6 mg subcutaneous once weekly
- Efpeglenatide 6 mg injection every 2 weeks
- Efpeglenatide 8 mg injection every 2 weeks
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.52 (-2.33 to 1.31) | 0.30 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.83 (-1.87 to 0.36) | 0.41 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -2.22 (-6.60 to 2.37) | 0.68 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -3.34 (-8.14 to 1.83) | 0.90 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 4.44 (0.86 to 16.70) | 0.32 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 3.87 (0.96 to 11.38) | 0.48 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 4.50 (0.17 to 140) | 0.17 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.62 (0.13 to 55.59) | 0.36 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.65 (0.23 to 1.80) | 0.66 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.88 (0.62 to 6.03) | 0.45 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.85 (1.87 to 22.99) | 0.23 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 8.87 (1.75 to 68.77) | 0.19 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.94 (0.83 to 4.70) | 0.41 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.32 (0.89 to 6.52) | 0.36 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 2.74 (0.69 to 12.10) | 0.40 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.66 (0.04 to 7.45) | 0.53 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 4.60 (0.18 to 136) | 0.22 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -3.28 (-12.87 to 7.07) | 0.46 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -6.10 (-13.37 to 2.01) | 0.38 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 11.10 (1.08 to 49.66) | 0.50 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 5.07 (0.75 to 26.15) | 0.37 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.64 (0.09 to 22.74) | 0.43 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.68 (0.15 to 2.88) | 0.75 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.59 (1.79 to 7.55) | 0.50 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.03 (1.06 to 9.76) | 0.61 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.20 (0.50 to 3.00) | 0.69 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.91 (0.59 to 6.11) | 0.52 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 1.09 (0.14 to 7.27) | 0.64 |
Trials
- AMPLITUDE-MA 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise2017 · 406 randomized · 56 weeks
- NCT02075281A 20-week, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Safety and Efficacy of HM11260C on Body Weight in Obese Subjects Without Diabetes2014 · 297 randomized · 20 weeks